JMP Securities Upgrades Enanta Pharmaceuticals (ENTA) to Market Outperform

Go back to JMP Securities Upgrades Enanta Pharmaceuticals (ENTA) to Market Outperform

Barclays Downgrades Enanta Pharmaceuticals (ENTA) to Underweight

October 23, 2015 7:00 AM EDT

Barclays downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Equalweight to Underweight with a price target of $16.00 (from $45.00).

For an analyst ratings summary and ratings history on Enanta Pharmaceuticals click here. For more ratings news on Enanta Pharmaceuticals click here.

Shares of Enanta Pharmaceuticals closed at $23.90 yesterday.

... More

Enanta Pharma (ENTA) Halted on Second LUDP

October 22, 2015 3:30 PM EDT

Enanta Pharma (NASDAQ: ENTA) Halted on Second LUDP

... More

Enanta Pharma (ENTA) Drops Over 50%

October 22, 2015 3:29 PM EDT

Enanta Pharma (NASDAQ: ENTA) shares dropped over 50% after the FDA warned of serious liver injury risk with Viekira Pak.

... More

Enanta Pharma (ENTA) triggers limit-up, limit-down trading pause

October 22, 2015 3:14 PM EDT

Enanta Pharma (NASDAQ: ENTA) triggers limit-up, limit-down trading pause. The activity is related to Abbvie news.

... More